Admissible two-stage designs for phase II cancer clinical trials

Statistics in Medicine

Volumn 23, Issue 4, 2004, Pages 561-569

  Jung, Sin Ho ^a   Lee, Taiyeong ^b   Kim, Kyung Mann ^c   George, Stephen L ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAS INSTITUTE INC   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Bayes design; Compromise design; Minimax design; Optimal design; Sequential design

Indexed keywords

CYTOTOXIC AGENT;

ARTICLE; BAYES THEOREM; CANCER RESEARCH; CLINICAL STUDY; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; HUMAN; MEDICAL ETHICS; METHODOLOGY; PHASE 2 CLINICAL TRIAL;

BAYES THEOREM; CLINICAL TRIALS, PHASE II; HUMANS; MODELS, STATISTICAL; NEOPLASMS; RESEARCH DESIGN;

EID: 1142275380     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1600     Document Type: Article

References (10)

1. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 1989; 10:1-10.
2. Jung SH, Carey M, Kim KM. Graphical search for two-stage designs for phase II clinical trials. Controlled Clinical Trials 2001; 22:367-372.
3. Gehan EA. The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent. Journal of Chronic Diseases 1961; 13:346-353.
4. Lee YJ, Staquet M, Simon R, Cantane R, Muggia F. Two stage plans for patient accrual in phase II cancer clinical trials. Cancer Treatment Reports 1979; 63:1721-1726.
5. Fleming TR. One sample multiple testing procedures for phase II clinical trials. Biometrics 1982; 38:143-151.
6. Chang MN, Therneau TM, Wieand HS, Cha SS. Designs for group sequential phase II clinical trials. Biometrics 1987; 43:865-874.
7. Spiegelhalter DJ, Freedman LS, Blackburn PR. Monitoring clinical trials: conditional or predictive power? Controlled Clinical Trials 1986; 7:8-17.
8. Thall PF, Simon R. A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials. Controlled Clinical Trials 1994; 15:463-481.
9. Herson J. Predictive probability early termination plans for phase II clinical trials. Biometrics 1979; 35: 775-783.
10. DeGroot MH. Optimal Statistical Decisions. McGraw-Hill: New York, 1970.